Business Wire

MAVENIR

21.5.2021 05:02:10 CEST | Business Wire | Press release

Share
Mavenir Powering the First Smart City in Thailand With 5G Open RAN Integration Across mmWave Private Network

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that it’s working with National Telecom Public Company Limited (NT), a state-owned telecommunications company, 5GCT , a local partner specialized in delivering end-to-end 5G Smart Cities and Cisco Systems (Thailand), a leading networking company, to launch the first 5G Open RAN Smart City in Ban Chang, Thailand.

The launch of the 5G Smart City creates synergies between public and private sectors for a fully functional smart city. The city of Ban Chang, is connected to a motorway linking Thailand’s two largest cities: Pattaya and Bangkok. The location is within close proximity to U-Tapao International Airport, Map Ta Phut Industrial Zone and the new master planned Ban Chang Smart City that are strategically important infrastructure for the Digital Economy in Thailand and the Eastern Economic Corridor (EEC). These characteristics make Ban Chang the perfect city to take advantage of 5G use cases across industrial robots, factory automation, remote telemedicine, aviation, logistics and agriculture. Industry leaders are terming the development the ‘Silicon Beach ’ of Asia.

The Ban Chang Smart City 5G Private Network operates on Millimeter wave (mmWave) spectrum, spectrum which is ideally suited for a network operating Internet of Thing (IoT) sensors, drones and smart poles, all applications which require fast data uplink to the core for realtime analysis and city management.

Mavenir provided a cloud-native, open architecture-based Private Network solution that enabled TOT1 to reach the promise of 5G. The software-based platform enabled the transformation of the mobile communication private network into a completely virtualized environment, where devices, applications, and services run on an automated network using open architecture, containers, and artificial intelligence (AI). Mavenir’s end-to-end 5G Open RAN, Millimeter wave (mmWave) radios and 5G Core with Open API technology standards, in-sync with the cloud-native solutions supporting private On-Premise applications delivers Smart City concepts such as real-time diagnostics of traffic, public safety, digital signage and sensitive environmental conditions.

TOT’s IP transport infrastructure vendor and a key Mavenir technology partner, Cisco, provided switching hardware and application services to enable the ‘smart’ components of the 5G solution.

Mavenir’s Aniruddho Basu, GM of its Emerging Business Unit , said “We are proud to be part of this ambitious 5G project which sees a whole city connected on a series of 5G applications running in parallel. Connectivity is at the heart of this deployment - connecting people, communities, government services, and private sector services through local government data combined with new data acquired through Internet of Things (IOT), sensors, drones, and external collected data, to fully analyze it for proper city management and citizen knowledge.”

Commenting on the announcement, Shannon Kalayanamitr, Chief Executive Officer at 5GCT , said “At 5GTC, we are driven to strengthen the potential of Thailand through high speed 5G. The partnership with Mavenir as an infrastructure provider enables us to deliver robust, secure and reliable 5G Private Network infrastructure across enterprises, including smart city applications, industry 4.0 applications - automated industry and modern medicine.”

Taweewat Chantaraseno, Managing Director, Thailand & Indochina, Cisco Systems (Thailand), said “We are delighted to be part of the first 5G smart city in Thailand. With the partnership with Mavenir and Cisco Connected Communities Infrastructure (CCI), the host of Smart City can create a single, secure communications network to support all needs that are simpler to deploy and manage from end-to-end visibility, ranging from smart kiosks and outdoor Wi-Fi, to smart street lighting, parking, waste and more. Smart city infrastructure is enabling efficiency, cost reduction and improved living for city occupants and network infrastructure platform helps create these efficiencies.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.

Visit: www.mavenir.com

1 TOT and CAT Telecom recently merged under National Telecommunications Public Company Limited (NT) a Thai Government Telecom service provider

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye